Please login to the form below
Provention Bio
This page shows the latest Provention Bio news and features for those working in and with pharma, biotech and healthcare.
FDA approves first drug to delay onset of type 1 diabetes
Provention Bio’s Tzield delayed the average onset of type 1 diabetes by over four years. ... The US Food and Drug Administration (FDA) has approved Provention Bio’s Tzield (teplizumab-mzwv) as the first and only immunomodulatory treatment to delay
Latest news
-
FDA rejects Provention Bio’s type 1 diabetes prevention drug
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) denying approval for Provention Bio’s type 1 diabetes (T1D) prevention drug teplizumab. ... goal,” said Ashleigh Palmer, co-founder and chief executive officer of
-
FDA panel backs Provention Bio’s type 1 prevention drug teplizumab
On top of that, Provention Bio also submitted safety data for teplizumab in another indication, with the panelists commenting this could not be used to make a good comparison. ... Nevertheless, the Provention Bio’s chief executive oficer Ashleigh
-
Provention Bio wins PRIME designation for type 1 diabetes prevention drug
Meanwhile J&J partnered Crohn's drug flops in phase 2. Provention Bio has announced its lead candidate PRV-031 (teplizumab) has been granted Priority Medicines (PRIME) designation from the European ... We are very pleased the EMA recognises the
-
Tiziana joins type 1 diabetes prevention field
Cites potential advantages. Biopharma investors were recently wowed by data from a pipeline drug from Provention Bio which could delay the onset of type 1 diabetes in at-risk patients – and ... The share price of Provention Bio doubled last month
-
Type 1 diabetes prevention promise sends Provention Bio soaring
The share price of Provention Bio doubled yesterday after it released data which showed its immunotherapy PRV-031 (teplizumab) could delay the onset of of type 1 diabetes in children and ... Jeffrey Bluestone, a distinguished diabetes researcher and a
More from news
Approximately 6 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
The impact of COVID-19 on clinical trials
In one example, Provention Bio was forced to temporarily pause a phase 3 study evaluating its investigational therapy for type 1 diabetes.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
New hires at bluebird bio, BioNTech and Provention Bio
projects. Provention Bio. Provention Bio has appointed Jason Hoitt as its chief commercial officer. ... one diabetes (T1D) patients and at-risk individuals and, in parallel, advance our business development efforts for teplizumab,” said Ashleigh Palmer,
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Evoke Mind+Matter
We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
